EUVIMEDEUVIMED entdecken
Crossref

Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor

Angelina Tjokrowidjaja iD, M L Friedlander iD, Jonathan A Ledermann iD, Robert L Coleman iD, Mansoor R Mirza iD, Ursula A Matulonis iD, Eric Pujade-Lauraine iD, Sarah J Lord iD, Clare L Scott iD, Sandra Goble, Whitney York, Chee K Lee iD und 1 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.01182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Angelina Tjokrowidjaja und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Ovarian Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Cancer antigen-125 (CA-125) is recommended by treatment guidelines and widely used to diagnose ovarian cancer recurrence. The value of CA-125 as a surrogate for disease progression (PD) and its concordance with radiologic progression are unclear, particularly for women with platinum-sensitive relapsed ovarian cancer (PSROC) who have responded to chemotherapy and treated with maintenance poly(ADP-ribose) polymerase inhibitor (PARPi). METHODS In this pooled analysis of four randomized trials of maintenance PARPi or placebo (Study 19, SOLO2, ARIEL3, and NOVA), we extracted data on CA-125 PD as defined by Gynecologic Cancer InterGroup criteria and RECIST v1.1. We evaluated the concordance between CA-125 and RECIST PD and reported on the negative predictive value (NPV) and positive predictive value (PPV). RESULTS Of 1,262 participants (n = 818 PARPi, n = 444 placebo), 403 (32%) had CA-125 PD, and of these, 366 had concordant RECIST PD (PPV, 91% [95% CI, 88 to 93]). However, of 859 (68%) without CA-125 PD, 382 also did not have RECIST PD (NPV, 44% [95% CI, 41 to 48]). Within the treatment arms, PPV remained high (PARPi, 91% [95% CI, 86 to 94]; placebo, 91% [95% CI, 86 to 95]) but NPV was lower on placebo (PARPi, 53% [95% CI, 49 to 57]; placebo, 25% [95% CI, 20 to 31]). Of 477 with RECIST-only PD, most (95%) had a normal CA-125 at the start of maintenance therapy and the majority (n = 304, 64%) had CA-125 that remained within normal range. Solid organ recurrence without peritoneal disease was more common in those with RECIST-only PD than in those with CA-125 and RECIST PD (36% v 24%; P < .001). CONCLUSION In patients with PSROC treated with maintenance PARPi, almost half with RECIST PD did not have CA-125 PD, challenging current guidelines. Periodic computed tomography imaging should be considered as part of surveillance, particularly in those with a normal CA-125 at the start of maintenance therapy and on treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsOvarian NeoplasmsHumansFemalePoly(ADP-ribose) Polymerase InhibitorsCA-125 AntigenResponse Evaluation Criteria in Solid TumorsNeoplasm Recurrence, LocalCarcinoma, Ovarian Epithelial

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsCA-125 AntigenAntineoplastic Agents

Autor:innen und Institutionen

  • National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia.
  • Australia New Zealand Gynecological Oncology Group, Camperdown, Australia.
  • University of New South Wales Clinical School, Prince of Wales Hospital, Sydney, Australia.
  • University College London (UCL) Cancer Institute and UCL Hospitals, London, United Kingdom.
  • Texas Oncology, US Oncology Network, The Woodlands, TX.
  • Department of Oncology, Rigshospitalet-Copenhagen University Hospital, Copenhagen, Denmark.

ORCID-Profile: Angelina Tjokrowidjaja, M L Friedlander, Jonathan A Ledermann, Robert L Coleman, Mansoor R Mirza, Ursula A Matulonis, Eric Pujade-Lauraine, Sarah J Lord, Clare L Scott, Chee K Lee

Zitieren

APA

Tjokrowidjaja, A., Friedlander, M. L., Ledermann, J. A., Coleman, R. L., Mirza, M. R., Matulonis, U. A., Pujade-Lauraine, E., Lord, S. J., Scott, C. L., Goble, S., York, W., Lee, C. K., & Gynecologic Cancer Intergroup Meta-Analysis Committee (2024). Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01182

Vancouver

Tjokrowidjaja A, Friedlander ML, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, et al. Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01182

BibTeX
@article{Tjokrowidjaja2024,
  author = {Tjokrowidjaja, Angelina and Friedlander, M L and Ledermann, Jonathan A and Coleman, Robert L and Mirza, Mansoor R and Matulonis, Ursula A and Pujade-Lauraine, Eric and Lord, Sarah J and Scott, Clare L and Goble, Sandra and York, Whitney and Lee, Chee K and Gynecologic Cancer Intergroup Meta-Analysis Committee, Gynecologic Cancer Intergroup Meta-Analysis Committee},
  title = {Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.01182}
}
Kostenlos starten →